Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Induction chemotherapy results in complete remission (CR) rates of 20% to 50% among patients with poor-risk AML. Selinexor is an oral selective inhibitor of nuclear export with promising single-agent activity. By inhibiting the primary export protein, XPO1, selinexor localizes and activates tumor su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2020-01, Vol.26 (1), p.54-60
Hauptverfasser:	Sweet, Kendra, Komrokji, Rami, Padron, Eric, Cubitt, Christopher L, Turner, Joel G, Zhou, Junmin, List, Alan F, Sallman, David A, Dawson, Jana L, Sullivan, Daniel M, Chavez, Julio, Shah, Bijal D, Lancet, Jeffrey E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cytarabine - administration & dosage Daunorubicin - administration & dosage Female Humans Hydrazines - administration & dosage Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - pathology Male Maximum Tolerated Dose Middle Aged Patient Safety Survival Rate Tissue Distribution Treatment Outcome Triazoles - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!